Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Other Operating Expenses (2020 - 2025)

Historic Other Operating Expenses for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $1.6 million.

  • Lyell Immunopharma's Other Operating Expenses rose 11794.52% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 6622.05%. This contributed to the annual value of $3.3 million for FY2024, which is 1860.22% up from last year.
  • Per Lyell Immunopharma's latest filing, its Other Operating Expenses stood at $1.6 million for Q3 2025, which was up 11794.52% from -$1.1 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Other Operating Expenses registered a high of $1.6 million during Q3 2025, and its lowest value of -$1.1 million during Q2 2025.
  • Its 5-year average for Other Operating Expenses is $727631.6, with a median of $758000.0 in 2021.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 42511.21% in 2022, then plummeted by 20881.15% in 2025.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Other Operating Expenses stood at $798000.0 in 2021, then soared by 51.63% to $1.2 million in 2022, then tumbled by 47.02% to $641000.0 in 2023, then decreased by 19.97% to $513000.0 in 2024, then surged by 210.14% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, -$1.1 million for Q2 2025, and $119000.0 during Q1 2025.